EPISODE · Oct 20, 2023 · 11 MIN
Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles
from Oncology Data Advisor · host i3 Health
In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.
What this episode covers
In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.
NOW PLAYING
Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles
No transcript for this episode yet
Similar Episodes
Jun 20, 2026 ·2m
Jun 15, 2026 ·3m
Jun 14, 2026 ·2m
Jun 13, 2026 ·3m
Jun 12, 2026 ·3m
Jun 11, 2026 ·3m